Search results for "RADIATION"

Secondary thyroid carcinoma after treatment for childhood cancer

1998

Background Second malignant neoplasms (SMNs) have become a primary concern in evaluating long-term effects of treatment in pediatric oncology. Thyroid carcinoma has proven to be a common SMN. Methods. In a multicenter study involving 58 hospitals in Germany, Austria and Switzerland, 18 of 239 (7.5%) SMNs documented following first malignant neoplasm (FMN) in childhood were thyroid carcinoma. Results. The age at diagnosis of FMN ranged from 1 to 15 years. Eleven patients were female. Six children had survived Hodgkin disease, seven acute leukemia, two Ewing sarcoma and three various other tumors. Fifteen of the 18 patients had been treated with radiotherapy to the head and neck region. The t…

Health status of young children with cancer following discontinuation of therapy.

1987

This paper reports late effects and health status of 198 children who had cancer or leukemia diagnosed under 2 years of age and their therapies electively withdrawn. This series (92 neuroblastoma (NBL), 57 Wilms' tumor (WT), 46 acute lymphoblastic leukemia (ALL), and 3 non-Hodgkin's lymphoma) was followed for 1-12 years after discontinuation of therapy. Thirty-three children were diagnosed before 1973, 92 between 1973 and 1977, and 73 after 1977 in 16 Italian Pediatric Oncology Centers. As of December 1983, 176 children were reported to be alive and without evidence of primary cancer by physicians responsible for their care. One child died from a second primary tumor, two from late recurren…

The effect of overall treatment time in radiotherapy for localized prostate carcinoma

1991

Short fractionated radiotherapy versus multiple fractionated radiotherapy in patients with bone metastases: a meta-analysis of randomized clinical tr…

2003

In Reply to Belkacemi and Tsoutsou

2018

Changing trends in the national practice for external beam radiotherapy for children with central nervous system tumours in Spain: results from the c…

2003

In the literature: May 2016

2016

Radiotherapy as single modality was considered the standard of care for low-grade gliomas, a mixed population of low proliferative tumours including oligodendrogliomas, oligoastrocytomas and grade 2 astrocytomas. However, a recently reported trial in the New England Journal of Medicine indicates1 that the addition of procarbacine, lomustine (CCNU) and vincristine, a combination known by its acronym, PCV, significantly prolongs survival in patients with low-grade glioma. When this trial was initially reported in 2012, after a median follow-up of almost 6 years, according to the estimated number of events needed to analyse the results, a significant difference in progression-free survival (PF…

Primary optic nerve sheath meningioma

2007

BACKGROUND. Radiotherapy (RT) has occasionally been practiced in the treatment of optic nerve sheath meningioma (ONSM). Recently, stereotactic fractionated RT (SFRT) has been introduced as a tool with better precision for RT delivery. A comprehensive review was undertaken to provide more insight into this matter. METHODS. A literature search was performed to identify reports dealing with both clinical aspects (diagnosis) and treatment in ONSM, focusing on RT in primary (p)ONSM. In particular, major emphasis was placed on the role of SFRT in pONSM. RESULTS. SFRT was capable of achieving excellent local tumor control, with improved/stable functional capacity in ≥80%, accompanied with very low…

MR-based biomarkers in the diagnosis and the evaluation of the therapeutic response to radiotherapy (ETRR) in prostatic carcinoma (PCa): Implementati…

2009

e16136 Background: ETRR in PCa remains a challenging task. New biomarkers in the form of metabolites, detected with Proton Magnetic Resonance Spectroscopy (1H-MRS), and quantitative Apparent Diffusion Coefficient (ADC), determined with Diffusion-Weighted Magnetic Resonance Imaging, could be of value in the ETRR for PCa. Methods: Twenty-one men with biopsy proven localized PCa were examined before external radiotherapy. 3D-1H-MRS was performed at 3.0T without endorectal coils. The delivered radiotherapy dose was 78 Gy in 39 fractions with 6 MV photons. MR follow-up examinations up to 36 months post-radiotherapy were performed. For the pre-clinical study, healthy rat prostate was studied in …

Brain metastases following interleukin-2 plus interferon-alpha-2a therapy

2003

Abstract This study analyses the frequency and therapy of brain metastases in 94 stage IV melanoma patients after treatment with high-dose interleukin-2 (IL-2) and interferon-α (IFN-α) within three subsequent trials between 1990 and 1995. Central nervous system (CNS) metastases occurred in 28 patients (30%) during the potential follow-up period of 6 years. Time to occurence of brain metastases varied between 1 and 53 months, with a median of 10 months. Of 28 patients, 19 had